Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : CEO Battles Fallout From Data Manipulation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/18/2019 | 07:15am EDT

By Denise Roland and Tom Burton

Novartis AG Chief Executive Vas Narasimhan has spent part of his 18 months at the helm of the drug giant cleaning up issues that emerged before his watch. Now, he is facing a storm of his own making.

Dr. Narasimhan said on a call with analysts earlier this month that the company kept a data-manipulation issue under wraps while the Food and Drug Administration completed its review of Novartis's Zolgensma, the world's most expensive drug. The Swiss company has said it wanted to finish its own review before alerting the FDA, which it eventually did.

That timeline, however, has now triggered scrutiny by the regulator and drawn the ire of a handful of prominent politicians, casting a shadow over Dr. Narasimhan's short tenure as CEO.

"He's certainly in big danger of losing credibility," said Brad Loncar, an investor who runs an exchange-traded fund of biotech companies. "They've handled this in just about the worst way possible." Mr. Loncar doesn't own shares in Novartis.

The FDA has referred the Zolgensma matter to its Office of Criminal Investigations to begin a preliminary inquiry, according to a person familiar with the events. Submitting false data to the agency as part of a new-drug application could be a crime if investigators prove the actions were intentional and not an oversight.

Novartis says it hasn't been notified of the referral. The FDA declined to comment.

"Submitting complete information to the FDA is sacrosanct to the agency, " said David Gortler, a former FDA official.

The manipulation occurred at AveXis, a separate company that developed the drug and that Novartis later bought. Dr. Narasimhan has said that the lag in telling the FDA about the issue was unrelated to the approval timeline for Zolgensma. Novartis has said those responsible for the manipulation are being ousted.

"We tried to do all of the right things," Dr. Narasimhan said on the analyst call. He declined to comment for this article.

The episode is especially testing for Dr. Narasimhan because he has made it his goal to rebuild trust in the company. One of his first tests as CEO was handling the revelation that Novartis paid $1.2 million to Michael Cohen, President Trump's former personal lawyer, for what the company called insight into the administration's health-care policy. He called the decision -- which was made before he became CEO and in which he says he wasn't involved -- a mistake.

He is also presiding over negotiations with the U.S. to settle a long-running lawsuit alleging Novartis treated doctors to lavish dinners and other events in return for boosting prescriptions. The company recently set aside $700 million for a settlement.

Dr. Narasimhan, a 42-year-old Harvard-educated medical doctor, made a splash at Novartis after taking the top job. He promised a technology-led reboot of the company's research and development and moved quickly to shed lower-growth businesses.

Shares in July hit their highest level since 2015, though they have retreated somewhat since. After the data manipulation issue was disclosed by the FDA earlier this month, shares fell 2.5%.

Dr. Narasimhan is deeply invested in the success of Zolgensma, which forms a pillar of his strategy to pivot the company toward cutting-edge medicines. The $8.7 billion acquisition of AveXis, which developed Zolgensma and where the manipulation occurred, was one of his first big bets as CEO.

The drug is one of the first gene therapies to go on sale in the U.S., but it has also attracted scrutiny for its price tag -- at $2.1 million for the one-time treatment. It treats spinal muscular atrophy in small children by providing a working version of the faulty gene that causes the condition.

According to Novartis's account of the data manipulation, the issue was first raised internally in March. Dr. Narasimhan learned about the issue in early May, he told analysts on the call.

That data -- although a small set -- formed part of the dossier submitted to the FDA to seek approval for the drug. Dr. Narasimhan said he decided to run an internal investigation to determine whether the FDA file needed an update.

Weeks later, on June 28, Novartis told the FDA, which by then had approved the therapy. The agency has said the treatment can stay on the market since the issue doesn't change its view that Zolgensma is safe and effective.

The disclosure has caused a firestorm in Washington, at a time when drug prices have become a hot-button political issue. Five senators, including Democratic presidential candidates Sens. Elizabeth Warren of Massachusetts and Bernie Sanders of Vermont, recently wrote a letter to the FDA, urging the agency to make a forceful response to Novartis.

Separately, Sen. Chuck Grassley (R., Iowa) wrote to Dr. Narasimhan demanding information about the decision-making process and calling the episode reprehensible.

FDA officials are expected to meet congressional staff to discuss the issue in the coming week, according to an agency official.

Write to Denise Roland at Denise.Roland@wsj.com and Tom Burton at tom.burton@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
09/17NOVARTIS : Initiation of Novartis Entresto in-hospital included in the new ACC E..
AQ
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) -2-
DJ
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) Positive 16-week Prevent Results A..
DJ
09/16NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
AQ
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a -2-
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
DJ
09/13NOVARTIS : New Novartis data show Mayzent can help preserve mobility for longer ..
AQ
09/13NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
PU
More news
Financials (USD)
Sales 2019 47 014 M
EBIT 2019 13 827 M
Net income 2019 10 117 M
Debt 2019 17 463 M
Yield 2019 3,43%
P/E ratio 2019 18,7x
P/E ratio 2020 20,3x
EV / Sales2019 4,59x
EV / Sales2020 4,23x
Capitalization 198 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,57  $
Last Close Price 86,52  $
Spread / Highest target 24,2%
Spread / Average Target 9,31%
Spread / Lowest Target -5,78%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS15.63%198 222
JOHNSON & JOHNSON0.38%342 221
ROCHE HOLDING LTD.12.28%240 139
MERCK AND COMPANY7.98%211 257
PFIZER-16.38%201 883
NOVO NORDISK AS13.01%120 613